Status:
UNKNOWN
Impact of Nonselective Beta-blocker on Acute Kidney Injury in Cirrhotic Patients With Esophageal Varices
Lead Sponsor:
Taipei Veterans General Hospital, Taiwan
Conditions:
Acute Kidney Injury
Cirrhosis
Eligibility:
All Genders
20-85 years
Phase:
PHASE4
Brief Summary
We will include patients with EV and EVB. They will be randomized to EVL vs. NSBB for primary prevention And EVL+long-term NSBB vs. EVL+short-term NSBB for secondary prevention. 150 patients will be i...
Detailed Description
Despite advance in the prevention and treatment of esophageal variceal bleeding (EVB), it is still a majorcomplication of portal hypertension with the characteristic of a high mortality around 15\~20%...
Eligibility Criteria
Inclusion
- Criteria
- Age of 20 to 85 years
- Cirrhotic patients with esophageal varices regardless of bleeding event or not will be enrolled in this study.
Exclusion
- Terminal stage HCC/ other malignancy/ Stroke or active sepsis/ Chronic kidney disease stage 4 under renal replacement therapy/ Contraindications to non-selective beta-blockers/ A history of non-selective beta-blockers use, sclerotherapy, banding ligation, transjugular intrahepatic porto-systemic shunt, or shunt surgery/ Serum total bilirubin \>10 mg/dL/ Refractory ascites/ Hepato-renal syndrome/ Pregnancy/ Severe heart failure (NYHA Fc III/IV)/ Bronchial asthma or chronic obstructive pulmonary disease/ Second or third degree atrioventricular block/ Severe hypotension/ Refusal to participate
Key Trial Info
Start Date :
April 13 2015
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 30 2020
Estimated Enrollment :
170 Patients enrolled
Trial Details
Trial ID
NCT04074473
Start Date
April 13 2015
End Date
July 30 2020
Last Update
September 20 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Taipei Veterans General Hospital
Taipei, Taiwan, 11217